Downregulation of ACE2 in COVID-19 leads to decreased angiotensin 1-7 and increased angiotensin II levels (300), possibly worsening skeletal muscle damage and loss associated with inflammation and immobilization. This evidence concerns the gene ACE2 and COVID-19.